Please ensure Javascript is enabled for purposes of website accessibility

Why TherapeuticsMD's Stock Spiked Today

By Brian Feroldi - Updated Apr 16, 2019 at 8:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders are feeling giddy after management shared the bull case for owning its stock at an important investor conference.

Check out the latest TherapeuticsMD earnings call transcript.

What happened

Shares of TherapeuticsMD (TXMD -0.60%), a commercial-stage biopharma focused on women's health, rose 10% as of 3 p.m. EST on Thursday. The jump is most likely related to the company's presentation at the J.P. Morgan Healthcare Conference on Wednesday afternoon.

So what

TherapeuticsMD's management team presented investors with the bull case for owning its stock on Wednesday.

During its presentation, the company called out that it has three recently approved products -- Imvexxy, Bijuva, and Annovera -- that are either already on the market or expected to launch in 2019. Management believes that the potential addressable markets for these drugs are $20 billion, $25 billion, and $5 billion, respectively, in the U.S. alone.

Businesspeople watching a presentation on a large screen

Image source: Getty Images.

Management also shared data with investors showing that Imvexxy is off to a strong start. The drug is selling far faster compared to the ramp-up for other drugs in the women's-health space like Osphena and Intrarosa.

That messaging appears to be resonating with traders today.

Now what

2019 should be a pivotal year for the company. If management can ramp up sales of Imvexxy and successfully launch both Bijuva and Annovera, that will go a long way toward silencing the company's critics.

Personally, I'm rooting for TherapeuticsMD's success, but I want to see a few more quarters of data before I could call shares a buy. Until that happens, I'm content to remain cautious.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
TXMD
$9.90 (-0.60%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.